MedTrace Logo

To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population

NCT02937636 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2019-06-14

Study results available
· View outcomes & findings →

Summary

This single-centre, examiner-blind, randomized, stratified, two-treatment, parallel group clinical study will evaluate the efficacy of a 0.454% w/w stannous fluoride dentifrice compared to a reference dentifrice to control gingivitis (gingival bleeding and visual signs of gingival inflammation) in dentally and periodontally healthy adult volunteers over 12 weeks use in a Chinese population.

Conditions

  • Gingivitis

Interventions

OTHER

Stannous fluoride

Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride

OTHER

Sodium monofluorophosphate

Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

  • GSK Clinical Trials · GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2017-12-22
Completion
2017-12-22

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02937636 on ClinicalTrials.gov